Value investing message boards image Log on |  Join ($$) Stock market forums image VF "How To" Guide        Welcome, guest! Learn about guest access                       
ValueForum.com Home
• Related Discussion Forum Messages
As a ValueForum member, this section would contain CLVS message board posts where the ticker symbol CLVS has been mentioned by ValueForum members in posts. Learn more about guest access, and benefits of membership -- we hope you will consider joining ValueForum or trying out our service with a 24 hour trial pass.

• Latest CLVS SEC Filings

Filings Format Description Filing Date File/Film Number
SC 13D  Documents General statement of acquisition of beneficial ownership
Acc-no: 0000919574-18-006985 (34 Act)  Size: 394 KB
2018-11-05 005-86488
181160873
10-Q  Documents   Interactive Data Quarterly report [Sections 13 or 15(d)]
Acc-no: 0001558370-18-008187 (34 Act)  Size: 8 MB
2018-11-01 001-35347
181151352
8-K  Documents Current report, items 2.02 and 9.01
Acc-no: 0001157523-18-002209 (34 Act)  Size: 119 KB
2018-10-30 001-35347
181147007
8-K  Documents Current report, item 5.02
Acc-no: 0001193125-18-310715 (34 Act)  Size: 16 KB
2018-10-29 001-35347
181144799
SC 13G  Documents Statement of acquisition of beneficial ownership by individuals
Acc-no: 0001654954-18-011552 (34 Act)  Size: 69 KB
2018-10-25 005-86488
181137969
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000899243-18-026752 Size: 5 KB
2018-10-15
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000899243-18-026728 Size: 5 KB
2018-10-15
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000899243-18-026727 Size: 5 KB
2018-10-15
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000899243-18-026723 Size: 5 KB
2018-10-15
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000899243-18-026721 Size: 5 KB
2018-10-15
More CLVS SEC Filings


Related news from
Wed, 21 Nov 2018
14:02:02 +0000
Clovis' (CLVS) Rubraca Gets Another US Patent, Shares Up
Clovis Oncology's (CLVS) shares rise more than 5% following the issuance of a new patent for Rubraca in the United States for claims related to methods of treating cancer with its high dosage strength.
Wed, 21 Nov 2018
13:58:01 +0000
TESARO Shares Rally on Rumors of Potential Acquisition Offer
Per a Bloomberg report, TESARO (TSRO) may have received an acquisition offer. Shares rally on rumors.
Tue, 20 Nov 2018
13:07:00 +0000
Clovis Oncology Announces Second U.S. Patent Issued in Rucaparib High Dosage Strength Tablet Patent Family with Expiration in 2035
Clovis Oncology, Inc. (CLVS) announced today that the United States Patent and Trademark Office issued United States Patent 10,130,636 with claims directed to methods of treating cancer with high dosage strength rucaparib camsylate formulations. “We have multiple families of patents protecting Rubraca in the U.S., including composition of matter, salts/polymorphs, dosage forms and formulations, and methods of use, and we continue to add new patents, including this high dosage strength method of treatment patent,” said Patrick J. Mahaffy, President and CEO of Clovis Oncology. Rubraca is an oral, small molecule inhibitor of PARP1, PARP2 and PARP3 being developed in multiple tumor types, including ovarian, metastatic castration-resistant prostate, and bladder cancers, as monotherapy, and in combination with other anti-cancer agents.
Fri, 16 Nov 2018
20:32:12 +0000
9 Colorado companies make Deloitte’s list of fastest-growing tech companies
Of the nine Colorado companies on the list, five are software companies and two are in biotech or pharmaceuticals.
Fri, 16 Nov 2018
14:00:57 +0000
Gauging Analysts’ Views on Clovis Stock
In November, of the 12 analysts covering Clovis Oncology (CLVS) stock, seven have given it “buy” or higher ratings, and five have given it “hold” ratings.
Fri, 16 Nov 2018
12:30:56 +0000
What Clovis Oncology’s Bottom Line Trend Indicates
While Clovis received an income tax benefit of $1.23 million in the third quarter of 2017, it incurred an income tax expense of $13,000 in the third quarter of 2018. Clovis Oncology had a net income of -$90.37 million in the third quarter compared to -$59.06 million in the third quarter of 2017. Clovis Oncology’s net EPS were $1.24 in the third quarter of 2017.
Thu, 15 Nov 2018
19:41:05 +0000
Understanding Clovis Oncology’s Gross Margin Trend
For 2018 and 2019, Clovis Oncology (CLVS) is expected to generate revenues of $88.79 million and $165.13 million, respectively, compared to its revenue of $55.51 million in 2017.
Thu, 15 Nov 2018
19:41:05 +0000
How Clovis Oncology Is Positioned in November
Clovis Oncology (CLVS) is focused on bringing to market innovative anticancer agents. One of its products, Rubraca, has been approved for the treatment of recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer. In July, Clovis received EMA (European Medicines Agency) approval for its application for a variation to its marketing authorization of Rubraca.
Thu, 15 Nov 2018
19:41:05 +0000
Exploring Clovis Oncology’s Operational Performance
Clovis Oncology (CLVS) incurred selling, general, and administrative expenses of $42.49 million in the third quarter compared to $35.01 million in the third quarter of 2017. This increase was due to higher commercialization activities for Rubraca and preparation for its expected launch in Europe.
Wed, 14 Nov 2018
15:28:03 +0000
Tesaro, Clovis Rally on FDA Priority Review for Lynparza sNDA
PARP inhibitor makers get a boost following priority review for AstraZeneca???s (AZN) label expansion application for Lynparza as a first-line maintenance treatment for ovarian cancer.
Tue, 13 Nov 2018
18:41:06 +0000
AstraZeneca's Lynparza Gets Priority Review in 1st Line Use
AstraZeneca (AZN) and partner Merck's sNDA looking for label expansion of Lynparza in the first-line setting gets FDA's priority review.
Mon, 12 Nov 2018
12:40:00 +0000
Recent Analysis Shows Clovis Oncology, Evertec, Etsy, Ring Energy, Ocular Therapeutix, and Destination Maternity Market Influences — Renewed Outlook, Key Drivers of Growth
NEW YORK, Nov. 12, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Mon, 12 Nov 2018
12:20:00 +0000
Clovis Oncology is Testing Rubraca(R) For Multiple Oncology Indications, Analysts Review and Target
NEW YORK, NY / ACCESSWIRE / November 12, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive ...
Fri, 09 Nov 2018
15:21:28 +0000
Portola Pharmaceuticals Stock Rose after Its Q3 2018 Results
On November 8, after Portola Pharmaceuticals released its third-quarter financial results, the stock price rose 21.41%. On November 8, Portola Pharmaceuticals stock price closed at $23.14, which was ~21.41% growth from its previous close of $19.06. On November 7, Portola Pharmaceuticals stock price closed at $19.06, which was ~2.80% growth from its previous close of $18.54. On November 7, the company hit its 52-week low of $18.18.
Fri, 09 Nov 2018
13:03:55 +0000
See what the IHS Markit Score report has to say about Clovis Oncology Inc.
Clovis Oncology Inc NASDAQ/NGS:CLVS
Wed, 07 Nov 2018
13:00:00 +0000
Clovis Oncology to Present at the Credit Suisse 27th Annual Healthcare Conference
Clovis Oncology, Inc. today announced that Patrick J. Mahaffy, Chief Executive Officer and President, will present at the 27th Annual Healthcare Conference on Wednesday, November 14, 2018 at 11:30 AM Mountain Time.
Tue, 06 Nov 2018
19:23:24 +0000
How Clovis Oncology Inc (CLVS) Stacks Up Against Its Market Cap Peers
The 700+ hedge funds and money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the second quarter, which unveil their equity positions as of June 30. We went through these filings, fixed typos and other more significant errors and identified the changes in hedge fund positions. Our extensive review […]
Tue, 06 Nov 2018
14:30:00 +0000
Big Biotech May Be After These Technologies
HENDERSON, NV / ACCESSWIRE / November 6, 2018 / Big biotech stock buybacks "have destroyed more than $12 billion in value, and generated no positive return in total, at least as a portfolio investment," ...
Tue, 06 Nov 2018
04:25:20 +0000
Edited Transcript of CLVS earnings conference call or presentation 30-Oct-18 8:30pm GMT
Q3 2018 Clovis Oncology Inc Earnings Call
Mon, 05 Nov 2018
16:01:44 +0000
Here's Why Clovis Oncology Stock Dropped a Whopping 60.4% in October
Three separate unfavorable events sent investors packing. Were things really that bad?



"ValueForum is an active, private, online discussion community for stock & bond market investing. In discussion forums divided into finely grained topics, you will find sophisticated investors trading tips, research, and due diligence on value stocks, income investments, forex, market news, and more. Join in - trade ideas, strategies, current news, via our unique message bulletin boards, stock ratings system, and other online tools specifically geared toward our community."

Random member testimonial: "There is power in numbers. It's obvious that most brokers don't have a clue of what they recommend to clients. Rarely do they own what they are talking about. Here at VF it's real. Real people with real positions giving their takes on the good w/ the bad. "Knowledge always beats strength" is a great quote. Here, at VF, I hope to see the sharing of knowledge become our strength." more testimonials »

Email / About | Privacy | Terms of Use | How To / FAQ | Msg Ticker | VF Home | My.vf | BDCs.vf | Energy.vf | REITs.vf | TA.vf
 
Nothing in ValueForum.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by ValueForum.com. ©2003 - 2018, Powered in part by Ticker TechnologiesContact Us

Stock Market Investing Forum - Trading Tips & Research - Online Message Boards